468 Capital’s Post

Australia makes up just 3% of the global pharmaceutical market - so what about the other 97%? 🌏 When it comes to digital health, going global is key. 🚀 In our latest episode, OneVentures Founding Partner & Director Paul Kelly dives into the world of biotech and digital health, explains why Aussie startups need to think BIG, and breaks down why tackling the massive US market is essential for Aussie startups. ✅ Tune in to learn more with Cheryl Mack from Aussie Angels and Maxine Minter from Co Ventures about angel and venture capital investing within biotech and digital health. 🎧 Thanks to our sponsors for helping to make this episode of First Cheque possible. Vanta, Turo

Our partner fund iThink VC, who is part of the Seedstars Capital platform, has been busy supporting innovative ventures across Latin America! Recent investments include: 🇺🇾 Xeptiva Therapeutics - Uruguayan scientific start-up raises $2.5M to develop cutting-edge veterinary vaccines, aiming to improve animal health across the region. 🇵🇾🇧🇴 BucksApp - Lands $1M in a pre-seed round. This Paraguayan-Bolivian fintech transforms large volumes of transactional data into actionable insights, helping banks find new opportunities for growth and sales. 🇵🇪 Price Lab (EPA18) - This Peruvian fintech has successfully closed its pre-seed round with $360K, led by iThink VC. Price Lab is revolutionizing in-store pricing strategies for retailers through AI, software, and devices designed to optimize sales. iThink VC continues to drive impactful innovation across various sectors in Latin America, and we are excited to see what’s next! Want to find out more about the investment? Head over to the comments! Juan Cruz Valdez Rojas, Jazmín Gustale Gill, Benjamin Langer, Daniela Moreno V #VentureCapital #TechInnovation #iThinkVC #EmergingMarkets #Startups #LatinAmerica #SeedstarsPortfolio

A recent article by The San Diego Union Tribune (linked below) had some interesting stats on the life science market: - During Q3 of 2024, there were 56 deals totaling $1.4B in San Diego County - While deals declined year over year by 5%, the value generated by SD’s startups increased by 14% - The top 9 VC deals during Q3 were by healthcare companies - The largest raises were by Candid Therapeutics ($370M on September 9th) and Element Biosciences ($277M ), followed by Vignette Bio ($105M), Autobahn Therapeutics ($101M), TRC ($90M) and Truvian ($74M) -Despite all of these fundraising rounds, 2024 is another consecutively slow year at the VC level – reasons for this include high interest rates, instability relating to the upcoming elections & increased regulatory pressure on M&A transactions -VC money is going to established teams or startups in later stages, which is causing more companies to stay private longer and the market is experiencing fewer large exits through IPO activity - Pitchbook’s AI analysis selected Element Biosciences and Resilience as two companies to have a successful IPO exit https://lnkd.in/gpTGeu4E

Big things ahead! 🥼💫♻️ Amorsui has raised an incredible $3.5 million in seed funding. We are excited to allocate the funds toward accelerating product innovation, expanding our market presence, and developing an AI-integrated net-zero medical supply marketplace ✅ The future is now! Check out the article below from FinSMEs to learn more ⬇️

Karius has secured $100m in Series C funding, with the investment round co-led by Khosla Ventures, 5AM Ventures, and Gilde Healthcare, and joined by new investor Seventure Partners and existing investor SoftBank Investment Advisers, General Catalyst, HBM Healthcare Investments, Blue Water Life Sciences, Innovation Endeavors, Waycross Partners, and others. Bloomberg News' Sarah McBride reports on how the funding allows Karius to address the rising demand from healthcare providers to expand access to the #KariusTest beyond the hospital setting. Additionally, it will facilitate research into the broader health implications of Karius' #mcfDNA technology beyond infectious diseases. #funding #biotech #healthcare https://lnkd.in/eSg_jN6Y

We're excited to share that Remepy has successfully raised a $10M Seed round, bringing their total funding to $15M. We are thrilled to be part of this company's journey as their pre-seed investors and to participate in this round as well. A big welcome to the new funds joining, NFX that led the round joined by Vine Ventures, L.P., PsyMed Ventures, Supernode Ventures, and Firstime VC. A big shoutout to the existing investors TechAviv, 97212 Ventures, StageNext Fund, Samsung Next and all the angels on board. Another big welcome to Dr. Danny Bar Zohar, Merck’s Global Head of R&D and Chief Medical Officer, who has joined Remepy's board. His expertise will undoubtedly propel the company's mission forward. Dr. Bar Zohar is joining world-class personas who are already on Remepy's scientific, advisory and company's board such as Former PM Naftali Bennett, Prof. Michal Schwartz, Jessica J. Federer and Jonathan MacQuitty. Remepy is pioneering the "hybrid drugs" category. The company's hybrid drug combine traditional drugs with its “digital molecules.” Digital molecules are therapeutic interventions that trigger physiological effects (aka MOAs, Mechanisms of Action) through the brain. These physiological changes have been known to enhance the effectiveness of traditional drugs. Hats off to Michal Tsur, Or Shoval, Prof. Amir Amedi, Shahar Shelly M.D and the entire Remepy team for reaching finalizing this round and reaching this important milestone. Your dedication and innovative approach are reshaping the pharma and health industries and has incredible potential to improve patient outcomes. For more details on how Remepy is pioneering the hybrid drug category and to learn more about the science behind it, visit Remepy's website (link in the comments)

Created to help the #lifesciences ecosystem thrive, CEOthreesixty is a moderated peer-to-peer advisory where CEOs in this space collaborate to solve their toughest business challenges. Capital fundraising was discussed most recently - take a look at real-world advisors driving measurable results. #lifesciences  #biotechnology  #pharmaceuticals  #medicaldevice  #peeradvisory  #venturecapital  #capitalraising

In our March meeting of the CEO Connection powered by CEOthreesixty, we had a special guest speaker addressing one of the most important topics facing early-stage Life Sciences CEOs – Capital fundraising and pitching their story. The group's Forum leaders, John Foley and David H. Crean called upon a VC fundraising expert Melanie Platt, Founder of Pitch Hackerz. Having raised more than $500M for early-stage technology and Life Sciences entities, Melanie laid it all out on the table for the CEOs and put to rest many misconceptions about fundraising an pitching to Venture funds in just 20 minutes. Melanie's style is unabashedly direct, honest, authentic, and refreshing. The CEO members and sponsor partners in the room walked away with invaluable insights.    Key Points conveyed by Melanie: ·     "VC’s need to understand what you have in 5 seconds." Convey your needs while ensuring you meet the fit of the VC’s thesis. ·     "VCs need to understand your differentiator - what makes you so special?" If you are building something revolutionary, now is the time to show it. ·     "Don’t ask VCs if you can jump on a quick call." - send them your info and make it easy as possible to say yes to you. ·     Make sure the info you send is easily digestible. ·     Your info needs to showcase "VC scale". Thank you, Mel! A big thanks to our partner sponsors and advisors in the ecosystem including Procopio, Cory, Hargreaves & Savitch LLP, Deloitte, Catalent Pharma Solutions, Sayva Solutions, Ty Summerlin, CFP®, Arrow Up Partners, LLC, and Cardiff Advisory LLC #mentoring #lifesciences #biotechnology #pharmaceuticals #medicaldevices #peeradvisory #venturecapital #capitalraising

In Q2, privately held drug developers raised an impressive $6.7 billion, marking the best quarter since early 2022! Despite heightened investor selectivity, the average financing round jumped to $94 million, driven by 27 mega rounds. While deal volumes dipped, the increase in crossover rounds indicates a promising market rebound. More biotechs are gearing up for IPOs, and new funds are emerging. The biotech funding landscape is looking bright. #BiotechFunding #VentureCapital #IPO #HealthcareInnovation

#fundingalert 💼Company: Remepy 💰Funding: $10Million ⚡Round: Seed 👥Investors: TechAviv, Fresh.fund, Samsung Next, StageNext Fund, 97212 Ventures, NFX, Vine Ventures, PsyMed Ventures, Supernode Ventures, and Firstime VC Remepy is a Leader in Hybrid PharmaceuticalsTM. They think that in the future, software programmes will be a crucial component of the therapies that pharmaceutical firms provide as Hybrid DrugsTM. Remepy is at the forefront of the development of hybrid pharmaceuticals, which mix traditional medications with personalised digital therapy to improve the efficacy of pharmacological treatments. The company is led by Michal Tsur and Or Shoval. Shahar Shelly M.D, Johnathan Amit Kanarek, Ofer Tur-Sinai, Shai Erlich, Lior Benderski Read more -https://lnkd.in/gSKWPSHn To share your startup story write us on - contact@startuprise.io #Remepy #HybridPharmaceuticals #development #software #pharmacological #funding #fundingnews #news #startupnews #startup #startuprise